Market Research Logo

Sarcoidosis - Pipeline Review, H1 2016

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sarcoidosis Overview
Therapeutics Development
Pipeline Products for Sarcoidosis - Overview
Sarcoidosis - Therapeutics under Development by Companies
Sarcoidosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Sarcoidosis - Products under Development by Companies
Sarcoidosis - Companies Involved in Therapeutics Development
Araim Pharmaceuticals, Inc.
FirstString Research, Inc.
PharmaIN Corporation
Sarcoidosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABS-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cibinetide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eprodisate disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide for Sarcoidosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sarcoidosis - Recent Pipeline Updates
Sarcoidosis - Dormant Projects
Sarcoidosis - Discontinued Products
Sarcoidosis - Product Development Milestones
Featured News & Press Releases
Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA
Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy
Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring
Oct 10, 2013: Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sarcoidosis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Sarcoidosis - Pipeline by Araim Pharmaceuticals, Inc., H1 2016
Sarcoidosis - Pipeline by FirstString Research, Inc., H1 2016
Sarcoidosis - Pipeline by PharmaIN Corporation, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Sarcoidosis Therapeutics - Recent Pipeline Updates, H1 2016
Sarcoidosis - Dormant Projects, H1 2016
Sarcoidosis - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Sarcoidosis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Sarcoidosis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Sarcoidosis - Pipeline Review, H1 2016’, provides an overview of the Sarcoidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Sarcoidosis
The report reviews pipeline therapeutics for Sarcoidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Sarcoidosis therapeutics and enlists all their major and minor projects
The report assesses Sarcoidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Sarcoidosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Sarcoidosis
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;